Large regenerative nodules developing in Budd-Chiari syndrome (BCS) represent hepatocyte hyperplasia secondary to hepatic vein outflow obstruction. In BCS, hepatic vein occlusion → sinusoidal congestion → periportal sinusoidal dilation → compensatory hepatocyte hyperplasia develops in areas where portal perfusion is preserved. These nodules are benign in nature but may mimic HCC. The caudate lobe has separate venous drainage (drains directly to IVC) and is therefore usually spared, showing compensatory hypertrophy. FNH-like nodules may also develop in BCS.
Age Range
20-60
Peak Age
35
Gender
Female predominant
Prevalence
Uncommon
In BCS, hepatic vein occlusion increases sinusoidal pressure — centrilobular (zone 3) hepatocytes undergo ischemic necrosis. The periportal zone (zone 1) is relatively preserved as it receives dual blood flow from portal vein and hepatic artery. Hepatocytes in these preserved areas show compensatory hyperplasia — forming large regenerative nodules. Arterial blood flow to nodules is increased (arterial buffer response in areas of decreased portal perfusion) — this forms the basis of arterial enhancement. The caudate lobe is privileged: it drains directly to IVC rather than hepatic veins — protected from sinusoidal congestion and shows prominent compensatory hypertrophy. In chronic BCS, these nodules may develop dysplasia and rarely transform to HCC.
The combination of caudate lobe hypertrophy and nodules that are hyperintense in arterial phase → isointense/hypointense in portal venous phase (flip-flop enhancement) in the setting of hepatic vein occlusion/thrombosis is the signature finding of Budd-Chiari regenerative nodules. T1 hyperintensity and hepatobiliary phase uptake confirm benign nature, absence of T2 hyperintensity excludes HCC.
Arterial hyperenhancement — nodule enhances more intensely than surrounding congested parenchyma. This finding may mimic HCC and lead to misdiagnosis without BCS clinical context.
Report Sentence
Arterially hyperenhancing nodules in the liver in the setting of hepatic vein occlusion are consistent with regenerative nodules associated with Budd-Chiari syndrome.
Nodules become isointense or hypointense in portal venous phase (flip-flop phenomenon). At this stage, surrounding congested parenchyma also starts to retain contrast and the nodule-parenchyma contrast reverses.
Report Sentence
Nodules hyperenhancing in arterial phase become isointense/hypointense in portal venous phase, and the flip-flop enhancement pattern is consistent with Budd-Chiari regenerative nodules.
T1 hyperintense nodules — due to copper accumulation (congested parenchyma cannot excrete copper, nodules store copper) or glycoprotein accumulation. This finding resembles dysplastic nodules in cirrhotic liver but BCS context is distinguishing.
Report Sentence
T1 hyperintense nodules are seen in the liver, consistent with Budd-Chiari regenerative nodules on the basis of copper accumulation.
Nodules are isointense or mildly hypointense on T2 — different from T2 hyperintensity of HCC. This finding supports benign regenerative nature.
Report Sentence
Nodules show iso/mildly hypointense signal on T2, different from typical T2 hyperintensity of HCC — supporting regenerative nature.
Contrast uptake in nodules on hepatobiliary phase with gadoxetic acid (Primovist/Eovist) — demonstrates presence of functional hepatocytes. Hepatobiliary phase uptake is decreased or absent in HCC. This finding is one of the most important MR criteria confirming the benign nature of BCS nodules.
Report Sentence
Contrast uptake in nodules on hepatobiliary phase confirms functional hepatocyte content and is consistent with benign regenerative nature.
Prominent caudate lobe hypertrophy with atrophy of right and left lobes — pathognomonic morphological finding of BCS. Lobes with impaired hepatic vein drainage become atrophic while the preserved caudate lobe grows compensatorily.
Report Sentence
Prominent compensatory hypertrophy of the caudate lobe with atrophy of right and left lobes is seen, consistent with morphological changes of Budd-Chiari syndrome.
Criteria
Regenerative nodules >1 cm diameter. Normal hepatocyte morphology preserved, no dysplasia.
Distinct Features
Completely benign, HCC transformation risk very low. Flip-flop enhancement typical. Hepatobiliary phase uptake present. Remains stable on long-term follow-up.
Criteria
Histological features resembling FNH — central scar, abnormal thick-walled arteries, bile ductules. Develops in BCS setting.
Distinct Features
Central scar may be seen on CT/MRI — enhancing fibrous core on delayed phase. Bright uptake on hepatobiliary phase. Distinguished from true FNH by BCS clinical context.
Criteria
Rarely in chronic BCS, regenerative nodules develop dysplasia → HCC. Increasing nodule size, T2 hyperintensity, or loss of hepatobiliary phase uptake are warning findings.
Distinct Features
Growth on follow-up, development of T2 hyperintensity, loss of hepatobiliary phase uptake suggest HCC transformation. AFP elevation may be an additional laboratory clue. Requires biopsy.
Distinguishing Feature
HCC is T2 hyperintense, BCS nodules are T2 iso/hypointense. HCC shows no uptake on hepatobiliary phase (hypointense defect), BCS nodules show uptake. AFP may be elevated in HCC. T1 hyperintensity due to copper accumulation is more common in BCS nodules. Capsule and washout in HCC vs flip-flop enhancement in BCS nodules.
Distinguishing Feature
FNH develops in normal liver without BCS context. Central scar in FNH is more prominent and T2 hyperintense. Both lesions show hepatobiliary phase uptake. Clinical context (hepatic vein occlusion, caudate lobe hypertrophy) is the key to differential diagnosis.
Distinguishing Feature
High-grade dysplastic nodule develops in cirrhotic liver, BCS nodules develop in BCS setting. Dysplastic nodules may be siderotic (T2 hypointense, blooming on SWI). Both groups may show arterial enhancement but hepatobiliary phase uptake is variable in dysplastic nodules (may be decreased).
Urgency
routineManagement
surveillanceBiopsy
Not NeededFollow-up
6-monthBCS regenerative nodules are benign in nature and do not require treatment in most cases. However, treatment of the underlying BCS is critical — anticoagulation, angioplasty/stent, TIPS, or transplantation may be needed. Monitoring nodules is important as dysplasia → HCC transformation may develop rarely. Increasing size, development of T2 hyperintensity, or loss of hepatobiliary phase uptake are warning findings requiring biopsy. 6-month MRI follow-up is recommended. AFP level may be helpful in monitoring.
Regenerative nodules in Budd-Chiari syndrome may carry risk of HCC development, requiring regular surveillance. Underlying anticoagulant therapy and Budd-Chiari management (TIPS, transplantation) is the primary treatment. Biopsy is considered when HCC is suspected. AFP monitoring is recommended.